Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for HER2+ breast cancer: phase 3 trial compares next-gen drug to standard therapy

NCT ID NCT06830889

First seen Jan 25, 2026 · Last updated May 18, 2026 · Updated 20 times

Summary

This phase 3 trial tests whether a new drug, BL-M07D1, works better than the current standard (T-DM1) for people with HER2-positive breast cancer that still has invasive cancer after initial chemotherapy. About 1,450 women aged 18-75 will be randomly assigned to one of the two treatments. The main goal is to see how long participants stay free of cancer recurrence. This is not a cure, as ongoing monitoring and potential further treatment are expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact

  • Jiangsu Province Hospital

    RECRUITING

    Nanjing, Jiangsu, China

    Contact

Conditions

Explore the condition pages connected to this study.